Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease


Leucine-rich repeat kinase-2 (LRRK2) mutations are a common cause of Parkinson's disease. Here we identify inhibitors of LRRK2 kinase that are protective in in vitro and in vivo models of LRRK2-induced neurodegeneration. These results establish that LRRK2-induced degeneration of neurons in vivo is kinase dependent and that LRRK2 kinase inhibition provides a potential new neuroprotective paradigm for the treatment of Parkinson's disease.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Identification of inhibitors of LRRK2 kinase.
Figure 2: LRRK2 kinase inhibition protects against LRRK2-induced neuronal toxicity.


  1. 1

    Gasser, T. Expert Rev. Mol. Med. 11, e22 (2009).

    Article  Google Scholar 

  2. 2

    Greggio, E. et al. Neurobiol. Dis. 23, 329–341 (2006).

    CAS  Article  Google Scholar 

  3. 3

    Smith, W.W. et al. Nat. Neurosci. 9, 1231–1233 (2006).

    CAS  Article  Google Scholar 

  4. 4

    West, A.B. et al. Hum. Mol. Genet. 16, 223–232 (2007).

    CAS  Article  Google Scholar 

  5. 5

    Whaley, N.R., Uitti, R.J., Dickson, D.W., Farrer, M.J. & Wszolek, Z.K. J. Neural Transm. Suppl. 70, 221–229 (2006).

    CAS  Article  Google Scholar 

  6. 6

    Mata, I.F., Wedemeyer, W.J., Farrer, M.J., Taylor, J.P. & Gallo, K.A. Trends Neurosci. 29, 286–293 (2006).

    CAS  Article  Google Scholar 

  7. 7

    Chin, P.C. et al. J. Neurochem. 90, 595–608 (2004).

    CAS  Article  Google Scholar 

  8. 8

    Imai, Y. et al. EMBO J. 27, 2432–2443 (2008).

    CAS  Article  Google Scholar 

  9. 9

    Smith, W.W. et al. Proc. Natl. Acad. Sci. USA 102, 18676–18681 (2005).

    CAS  Article  Google Scholar 

  10. 10

    Leclerc, S. et al. J. Biol. Chem. 276, 251–260 (2001).

    CAS  Article  Google Scholar 

  11. 11

    Wang, W. et al. Neuropharmacology 52, 1678–1684 (2007).

    CAS  Article  Google Scholar 

  12. 12

    Anand, V.S. et al. FEBS J. 276, 466–478 (2009).

    CAS  Article  Google Scholar 

  13. 13

    Covy, J.P. & Giasson, B.I. Biochem. Biophys. Res. Commun. 378, 473–477 (2009).

    CAS  Article  Google Scholar 

  14. 14

    Nichols, R.J. et al. Biochem. J. 424, 47–60 (2009).

    CAS  Article  Google Scholar 

  15. 15

    Reichling, L.J. & Riddle, S.M. Biochem. Biophys. Res. Commun. 384, 255–258 (2009).

    CAS  Article  Google Scholar 

Download references


We thank C. Burris and L. Lotta for packaging helper virus–free amplicons. C. Cook, K. Kehoe, J. Dunmore and C. Eckman provided technical support for some of the in vivo HSV studies. We also thank G. and K. Caldwell and S. Hamamichi for helpful discussions. This work was supported by grants from the US National Institutes of Health, P50NS38377, R01ES014470 (K.A.M.-Z.), R01-AG023593 (W.J.B.), R00-NS058111 (A.B.W.), NS36420 (H.J.F.) and Army Medical Research and Materiel Command, DAMD17-02-1-0695 (H.J.F.), the Mayo Foundation and the Michael J. Fox Foundation.

Author information




B.D.L., J.V., L.P., A.B.W., V.L.D. and T.M.D. designed the experiments. B.D.L., J.V., H.S.K., Y.I.L. and J.-H.S. generated data. K.A.M.-Z., W.J.B. and H.J.F. generated HSV-encoded LRRK2s. B.D.L. and J.V. analyzed data. B.D.L., V.L.D. and T.M.D. wrote the manuscript. All authors discussed the results and commented on the manuscript.

Corresponding authors

Correspondence to Valina L Dawson or Ted M Dawson.

Ethics declarations

Competing interests

T.M.D. is a paid consultant to Merck KGAA. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1–6, Supplementary Tables 1–3 and Supplementary Methods (PDF 1295 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Lee, B., Shin, JH., VanKampen, J. et al. Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease. Nat Med 16, 998–1000 (2010).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing